709-P: Improved Satisfaction and Perceived Usability with the Omnipod 5 Automated Insulin Delivery System Compared with Prior Therapy

Abstract

Type 1 diabetes (T1D) is a lifelong disease that requires constant monitoring. New technologies seeking to relieve this burden must be user-friendly and provide treatment satisfaction to enable widespread adoption, glycemic benefit, and long-term success. We assessed these parameters for the Omnipod 5 Automated Insulin Delivery System during a 3-month outpatient study of the system. Participants (N=240) with T1D aged 6-70y completed validated assessment tools at study start and end, including the Insulin Device Satisfaction Survey (IDSS), Diabetes Treatment Satisfaction Questionnaire (DTSQ), and System Usability Scale (SUS). Parents/guardians of participants aged 6-11.9y (children, N=83) and 12-17.9y (teens, N=42) were assessed as appropriate. Participants were aged (mean±SD) 25±17y, with T1D duration 12±11y and baseline A1C 7.4±0.9%. Perceived usability and satisfaction with the treatment regimen and device were significantly improved with the study system compared to prior therapy (Table). Improvements were also seen in the IDSS subscales for burden and inconvenience (both p<0.05). In addition to glycemic efficacy and safety of the Omnipod 5 System (reported previously), these results reveal significant improvement in usability and satisfaction, suggesting that this system may alleviate some of the burdens associated with existing treatment options for T1D.View largeDownload slideView largeDownload slide DisclosureS. A. Macleish: Advisory Panel; Self; Insulet Corporation. W. H. Polonsky: Advisory Panel; Self; Intarcia Therapeutics, Inc., Consultant; Self; Abbott Diabetes, ADOCIA, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Insulet Corporation, Lilly Diabetes, Novo Nordisk, Onduo LLC., Sanofi US. K. K. Hood: Consultant; Self; Cecelia Health, Cercacor, LifeScan Diabetes Institute. C. J. Levy: Advisory Panel; Self; Dexcom, Inc., Eli Lilly and Company, Employee; Spouse/Partner; AbbVie Inc., Other Relationship; Self; Dexcom, Inc., Research Support; Self; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. L. M. Huyett: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. T. Ly: Employee; Self; Insulet Corporation.FundingInsulet Corporation